IL-1 Inhibition in Early TNBC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions

Early Stage Triple Negative ER Low Breast Cancer

Interventions

DRUG

Anakinra (Kineret®)

100 mg/daily subcutaneously

Trial Locations (1)

RECRUITING

University Health Network-Princess Margaret Cancer Center, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER